ArticleFrontiers in pediatrics2025
Application of sirolimus in an infant presenting with a life-threatening lymphatic malformation of the head and neck: a case report.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extensive lymphatic malformations in the head and neck region pose a significant risk due to potential airway compression, and conventional treatment modalities have proven largely ineffective. Currently, systemic administration of sirolimus is recognized as a promising therapeutic approach for complex lymphatic malformations. Nevertheless, the appropriate dosage, optimal blood concentration, efficacy, and safety profile of sirolimus in pediatric patients remain inadequately characterized. In this report, we present a clinical case involving a 3-month-old male infant diagnosed with tongue lymphatic malformation, treated with sirolimus. It is noteworthy that the trough concentration of sirolimus is influenced by both genetic and non-genetic factors, including physiological and pathological conditions, as well as drug-food and drug-drug interactions in pediatric patients. Despite the sirolimus concentration below the target range during treatment, a reduction in tumor size was observed. Additionally, based on the patient's medical history, adjustments in medication, and liver function assessments, the pharmacist has excluded the likelihood of sirolimus-induced hepatotoxicity. This case underscores the safety and efficacy of sirolimus in managing extensive lymphatic malformations of the head and neck in infants. Regular monitoring and analysis of variations in sirolimus blood concentrations, coupled with long-term follow-up observations, are essential for enhancing treatment efficacy and minimizing toxicity risks.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.